New chemo cocktail targets Hard-to-Treat testicular cancer

NCT ID NCT00183820

Completed Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a combination of three chemotherapy drugs—gemcitabine, oxaliplatin, and paclitaxel—in people with advanced testicular cancer that has not responded to standard cisplatin-based treatment or has returned after treatment. The goal is to see if this drug combination can shrink tumors or slow the disease. The trial enrolls about 30 adults with refractory germ cell tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine, oxaliplatin, and paclitaxel
What this could lead to: If successful, this combination could offer a new treatment option for patients with testicular cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a small, early-phase study, so the combination may not prove effective enough for wider use. Chemotherapy side effects are expected and can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

germ cell tumor Neoplasms, Germ Cell and Embryonal testicular cancer testis refractory cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERM CELL NEOPLASM TESTICULAR CANCER

Contacts and locations

Locations

Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.